Zimmer Biomet Hits New 52-Week Low at $79.84 Amid Declining Performance

Zimmer Biomet Holdings, Inc. has reached a new 52-week low, trading at USD 79.84 as of April 29, 2026. This marks a significant decline for the mid-cap company, which operates within the Pharmaceuticals & Biotechnology sector. Over the past year, Zimmer Biomet's stock performance has been notably negative, with a decrease of 29.07%, contrasting sharply with the S&P 500's gain of 28.33%. The company's financial metrics reveal a challenging landscape. With a market capitalization of USD 27,939 million, Zimmer Biomet has a price-to-earnings (P/E) ratio of 30.00. The dividend yield stands at an impressive 18.46%, although the return on equity is relatively modest at 7.46%. The company has also reported a decline in net profit, with a decrease of 28.26% over the past nine months. Despite its current valuation, Zimmer Biomet has struggled with consistent underperformance against market benchmarks, including a return of -13.53% over the last year. The stock's 52-week high was recorded at USD 108.29, highlighting the extent of its recent downturn.